Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
BMC Cancer|August 13, 2011
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancerMarcia S Brose, Christopher M Nutting, Steven I Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013
Physician and stakeholder perceptions of conflict of interest policies in oncologyA Craig Lockhart, Marcia S Brose, Edward S Kim, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Phase II trial of sorafenib in advanced thyroid cancerVandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, et al.
Hormones & Cancer|March 20, 2016
pAKT Expression and Response to Sorafenib in Differentiated Thyroid CancerMark Yarchoan, Changqing Ma, Andrea B Troxel, et al.
Journal of the American Academy of Dermatology|May 22, 2012
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic studyEmily Y Chu, Karolyn A Wanat, Christopher J Miller, et al.
Cancer|April 16, 2018
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)Lori J Wirth, Makoto Tahara, Bruce Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2023
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety UpdateVicky Makker, Carol Aghajanian, Allen L Cohn, et al.
Pageof 8